Article Figures & Data
Figures
- FIGURE 1.
Status of administered chemotherapy to patient population in course of the study.
- FIGURE 2.
Serial myocardial 18FDG PET results of 58-y-old male patient with non-Hodgkin's lymphoma who submitted 3 times to whole-body PET/CT. Short-axis, horizontal long-axis, and vertical long-axis slices are displayed together with polar maps of the semiquantitative QPS software. Overlays of 20 myocardial segments, coronary artery territories, and myocardial walls are represented on top, middle, and bottom 2-dimensional polar maps, respectively. Patient was asymptomatic and completely free of any sign of cardiovascular diseases during observation period. After 18F-FDG injection in fasting conditions, with blood glucose levels never exceeding 100 mg/dL, a marked variability of regional myocardial uptake over time is evident.
- FIGURE 3.
Correlation between segmental uptake at first test and segmental uptake variations between subsequent tests.
- FIGURE 4.
Spatial heterogeneity of regional 18F-FDG uptake in LV myocardium. Frequency distribution of percent maximum 18F-FDG uptake indicates a large variability across LV myocardial segments, even excluding the apical region. This finding was observed in a similar fashion at all 3 scans.
Tables
First examination (mean ± SD) Second examination (mean ± SD) Third examination (mean ± SD) P value Characteristic 1–2 1–3 2–3 No. of patients 49 Age (y) 54.2 ± 16.3 BMI (kg/m2) 24.6 ± 4.1 24.5 ± 4.1 24.3 ± 3.8 0.57 0.45 0.66 Activity (MBq) 352 ± 81 331 ± 106 310 ± 79 0.05 0.001* 0.14 Glucose (mmol/L) 96 ± 14 101 ± 30 97 ± 16 0.23 0.65 0.28 Acquisition† (min) 70 ± 25 67 ± 21 74 ± 28 0.45 0.42 0.13 SUVMyo 8.6 ± 5.7 8.1 ± 5.5 7.7 ± 5.6 0.52 0.16 0.51 SUVLV 2.7 ± 0.7 2.6 ± 0.8 2.6 ± 0.8 0.37 0.32 0.85 SUVLiver 2.8 ± 0.6 2.8 ± 0.5 2.7 ± 0.5 0.80 0.18 0.20 RT between PET1 and PET2 (n = 5) Parameter Findings at PET1 Findings at PET2 P value SUVMyo 9.6 ± 4.3 11.0 ± 2.6 0.50 SUVLV 3.1 ± 0.4 2.9 ± 0.5 0.39 SUVLiver 3.1 ± 0.3 3.1 ± 0.7 0.97 Coefficient of variation (%) 20.8 ± 4.8 (n = 3) 21.2 ± 2.6 0.77 RT between PET2 and PET3 (n = 4) Parameter Findings at PET2 Findings at PET3 P value SUVMyo 11.6 ± 7.4 14.4 ± 7.3 0.45 SUVLV 2.9 ± 0.7 3.2 ± 0.6 0.45 SUVLiver 2.7 ± 0.5 2.5 ± 0.9 0.50 Coefficient of variation (%) 14.9 ± 2.9 (n = 3) 14.7 ± 3.5 0.96 Chemotherapy between PET1 and PET2 (n = 28) Parameter Findings at PET1 Findings at PET2 P value SUVMyo 7.7 ± 4.5 7.1 ± 4.3 0.49 SUVLV 2.5 ± 0.7 2.5 ± 0.8 0.80 SUVLiver 2.7 ± 0.6 3.1 ± 0.7 0.69 Coefficient of variation (%) 19.0 ± 8.8 (n = 13) 18.1 ± 4.4 0.60 Chemotherapy between PET2 and PET3 (n = 24) Parameter Findings at PET2 Findings at PET3 P value SUVMyo 7.5 ± 5.3 7.2 ± 5.3 0.81 SUVLV 2.4 ± 0.7 2.5 ± 0.9 0.74 SUVLiver 2.7 ± 0.5 2.6 ± 0.7 0.36 Coefficient of variation (%) 17.8 ± 6.0 (n = 11) 17.6 ± 5.9 0.80
Jump to section
Related Articles
Cited By...
- Imaging of Chemotherapy-Induced Acute Cardiotoxicity with 18F-Labeled Lipophilic Cations
- In Vivo Translation of the CIRPI System: Revealing Molecular Pathology of Rabbit Aortic Atherosclerotic Plaques
- Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation
- 18F-Fluorodeoxyglucose Imaging of Inflammation: Ready to Represent a Standard in Diagnosing Endocarditis?
- Is There an Association Between Clinical Presentation and the Location and Extent of Myocardial Involvement of Cardiac Sarcoidosis as Assessed by 18F- Fluorodoexyglucose Positron Emission Tomography?
- The Value of 18F-FDG PET/CT in the Assessment of Cardiac Malignancy Remains to Be Defined
- Suppression of 18F-FDG Myocardial Uptake Using a Fat-Allowed, Carbohydrate-Restricted Diet
- Heterogeneous Myocardial FDG Uptake and the Disease Activity in Cardiac Sarcoidosis
- High Intraindividual Variability of Global Myocardial 18F-FDG Uptake over Time
- Reply: High Intraindividual Variability of Global Myocardial 18F-FDG Uptake over Time